BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
|Articles|January 24, 2019
Pharmacy Practice in Focus: Health Systems
- January 2019
- Volume 8
- Issue 1
Progress in Treating Advanced Melanoma: Pharmacists
In the United States, about 13% of patients present with advanced melanoma (9% with regional disease and 4% with distant metastatic disease).
Advertisement
FACULTY:
LeAnn B. Norris, PharmD, FCCP, BCPS, BCOP, Clinical Associate Professor, University of South Carolina College of Pharmacy, Columbia, South Carolina
EDUCATIONAL OBJECTIVES:
At the completion of this activity, the participant will be able to:
- Identify the treatment options for patients with advanced melanoma
- Examine the latest clinical data for patients with advanced melanoma
- Explain the role of the pharmacist in supporting optimal treatment strategies in advanced melanoma management
TARGET AUDIENCE: Pharmacists
ACTIVITY TYPE: Application
RELEASE DATE: December 28, 2018
EXPIRATION DATE: January 12, 2020
ESTIMATED TIME TO COMPLETE ACTIVITY: 2.0 hours
FEE: This lesson is offered for free at
Articles in this issue
over 7 years ago
What Are Treatment Approaches to Liver Cancer?over 7 years ago
What Are the Implications of the MERINO Trial?over 7 years ago
Develop a Collaborative Pain Management Strategyover 7 years ago
Are You the Gentamicin Pharmacist?Advertisement
Related to this article
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
2
What the 2025-2030 Dietary Guidelines Mean for Heart Health
3
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
4
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
5